Processa Pharmaceuticals 주식 (NASDAQ: PCSA)

에 대한 최신 뉴스 Processa Pharmaceuticals (NASDAQ:PCSA) 주식

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Constellation Brands

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ANGO

BIGC

LEVI

PCSA

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 컨스텔레이션 브랜드(NYSE:STZ)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.

목요일 주목해야 할 주식: 컨스텔레이션 브랜드, 리바이 스트라우스 그리고 3종목

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02074012/Quhuo-0502-900x600-1.png" alt="" class="wp-image-12083" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02074012/Quhuo-0502-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02074012/Quhuo-0502-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/02074012/Quhuo-0502-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company is moving away from its original business of providing takeout dining drivers, but revenue for most of its major new initiatives contracted in the second half of 2024
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Quhuo's revenue fell 27% in the second half of last year, as its core on-demand delivery services fell by 25%</li>
<li>The company's car exporting business also suffered a setback during the six-month period, as its vehicle exports fell sharply following a strong start in 2023</li>
</ul>
To call&nbsp;Quhuo Ltd.&nbsp;(QH.US) a company in transition seems like understatement of the year, based on its&nbsp;<a href="https://www.prnewswire.com/news-releases/quhuo-reports-financial-results-for-the-second-half-and-full-year-2024-solidifying-core-business-driving-diversified-growth-through-innovation-302441066.html">latest results</a>&nbsp;for the second half of 2024 issued last week. Quhuo got its start by providing many of the thousands of takeout dining drivers who delivered meals for operators like Meituan and Ele.me.
The company has been moving away from that low-margin business these days, probably at least partly as Meituan, Ele.me and new entrant JD.com get pressured to provide better benefits to their drivers. It's looking to redeploy many of its drivers into deliverers of groceries and other goods, as reflected by its launch of a new partnership with beef provider Niu World last year.
But that's not all that Quhuo is doing. The company has also entered the homestay business, which appears to be the major force behind a doubling in its stock last September. It's also getting into new energy vehicle (NEV) exports, and ride hailing services, as well as providing housekeeping services.
While some of those new initiatives showed some promising results in the first half of last year, they appear to have lost much of that momentum in the second half, though it's hard to tell based on the way the company selectively gives out data. That's not hugely surprising, given that many of the new areas Quhuo is entering are already very competitive, combined with weakening consumer demand in a slowing Chinese economy.
As a result of those factors, none of the new initiatives have really amounted to much just yet, with Quhuo's core on-demand food delivery business still accounting for 93% of its revenue in the second half of last year. In its latest results, the company said "2024 marked a year of strategic transformation for Quhuo."
"In 2024, we focused on stabilizing our cash-generating businesses while scaling innovative ventures, achieving steady operations and notable improvements in key business lines," said founder and Chairman Leslie Yu.&nbsp;
Among its many new initiatives, the NEV export business looks the most intriguing, though it appears to have stalled a bit last year, no doubt due to the complexity of exporting used cars. The homestay business could also have some potential under a new platform the company rolled out last September, which lit a fire under Quhuo's stock, causing it to more than double in just a matter of days.
Still, the company's stock has lost more than 98% of its value since its 2020 IPO, during headier times when it wowed investors with its position as a key supplier of drivers to China's booming takeout dining industry.
That business continued to be Quhuo's bread-and-butter in the second half of last year, supplying 1.33 billion yuan ($183 million) out of the company's total of 1.43 billion yuan for the six-month period, according to the latest results. Unfortunately for Quhuo, both its overall and on-demand driver revenue were down sharply in the six-month period, the former by 27% and the latter by 25%. The company blamed the drop on its disposal of several underperforming service stations.
<h4 class="wp-block-heading">‘Repurposing' delivery infrastructure</h4>
Quhuo said it is in the process of "repurposing its delivery infrastructure for higher-value use … marking a shift from fulfillment service provider to supply chain enabler." That refers to the shift that we previously mentioned, away from providing drivers to takeout dining services to using its fleet to deliver products for other third parties.
So far, Niu World looks like the major new partner under the shift, though the company didn't give out any data on how much revenue that partnership actually brought in. "Following a successful pilot, the model is expected to drive revenue growth in 2025, paving a new path for expansion in Quhuo's food delivery business," the company said. "Future plans include expanding this model to other highly perishable food segments."
Meantime, revenue from the company's mobility services segment, a distant second in terms of contributors after on-demand delivery services, tumbled 57% in the second half of the year to 74.7 million yuan from 175 million yuan a year earlier. The company blamed the drop on a falling revenue from its vehicle export business, in a setback for that young initiative.
Quhuo launched the vehicle export business in 2023 and previously said it had exported 13,000 vehicles to markets like the Middle East and South America by the end of 2023, with 9,836 vehicles successfully delivered. But in its latest report, the company said it had shipped just 3,500 vehicles overseas by the end of 2024, which appears to refer to its exports for last year.
Such a big drop is disappointing but not too unexpected, as the big figure for 2023 exports was probably due to one-time business involving one or two major buyers with the initiative's launch. After that initial burst, Quhuo is now trying to create a more sustainable business by building up the necessary infrastructure to handle things like car inspections, reconditioning, exports and customs clearing in destination countries.
The company has set up reconditioning bases in the cities of Chengdu and Guangzhou, and launched a platform called Carnuxt to handle the business. This initiative could hold out big potential if Quhuo can build up the necessary infrastructure, since China is currently the world's biggest NEV market and many of those vehicles will start entering the used car market in the years ahead.
Then there's the homestay business, which Quhuo operates using a company it acquired called Chengtu. While that service was initially more generally focused, similar to Airbnb, Quhuo last year announced an initiative to turn it into a more segmented service focused on six key areas: care, e-sports, business travel, family, cinema and elegant retreat. That approach that targets specific types of travelers may also hold potential at some point. But revenue from the company's housekeeping and accommodation services division, which includes the homestay business, also fell 17% in the second half of last year to 22.9 million yuan from 27.5 million yuan a year earlier – hardly encouraging for a new area.
Quhuo managed to stay profitable during the second half of last year, with its net income rising to 48.1 million yuan from 11.7 million yuan a year earlier. But it had just 65 million yuan in cash at the end of last year, far less than its short-term debt totaling 113 million yuan. Investors weren't too excited about the latest report, with Quhuo's stock falling 7% in the three trading days after the announcement. At the end of the day, the company will need to show better progress on some of its many new initiatives to draw pique investor interest again.

Equities

Travel

Opinion

Quhuo's Transformation Story Hits Speed Bump Amid China Slowdown

WIIM

EQNR

Equinor shares are trading higher after the company announced the sale of its Peregrino Field stake for $3.5 billion.

Stifel analyst Jim Duffy maintains Columbia Sportswear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) with a Buy and lowers the price target from $91 to $75.

Price Target

Analyst Ratings

COLM

Stifel Maintains Buy on Columbia Sportswear, Lowers Price Target to $75

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/01/final-trades-uber-doordash-and-shell-plc.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown, CEO of Ritholtz Wealth Management, said Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) is up <a href="https://www.benzinga.com/quote/UBER">35% year-to-date</a>.
As recent news reported, Uber Technologies disclosed a multi-year strategic partnership with May Mobility on Thursday to scale autonomous vehicles.
Jenny Van Leeuwen Harrington, CEO of Gilman Hill Asset Management, LLC, said Shell plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) trades at 10 times earnings and has a 4.3% yield.
On the earnings front, Shell reported first-quarter earnings of $1.84 per share, which beat the analyst consensus estimate of $1.65 per share. The company reported quarterly sales of $69.23 billion, which missed the analyst consensus estimate of $79.13 billion. The company also announced the commencement of a share buyback program.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova of Virtus Investment Partners picked DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) as his final trade.
DoorDash will release its first-quarter financial results after the closing bell on Wednesday, May 7. Analysts expect the company to report quarterly earnings at 38 cents per share versus a year-ago loss of 6 cents per share. DoorDash projects quarterly revenue of $3.09 billion, compared to $2.51 billion a year earlier.
Price Action:
<ul>
<li>Uber shares fell 0.2% to close at $80.89 on Thursday.</li>
<li>Shell gained 0.5% to close at $64.80 during Thursday's session.</li>
<li>DoorDash shares gained 1.7% to close at $196.20 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45134238/top-2-real-estate-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Real Estate Stocks That May Keep You Up At Night In May</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

DASH

SHEL

UBER

DoorDash, Uber And An Energy Stock On CNBC's 'Final Trades'

LITM

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Benchmark analyst David Williams reiterates Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) from Hold to Hold.

Reiteration

LFUS

Benchmark Reiterates Hold on Littelfuseto Hold

Stifel analyst Brian Chin maintains Cohu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHU#NASDAQ">COHU</a>) with a Buy and lowers the price target from $35 to $28.

COHU

Stifel Maintains Buy on Cohu, Lowers Price Target to $28

DPRO

Draganfly shares traded lower after the company priced a $3.6M underwritten public offering at $2.10 per unit

<a href="https://www.benzinga.com/topic/warren-buffett">Warren Buffett</a> and <a href="https://www.benzinga.com/topic/cathie-woodhttps://www.benzinga.com/topic/cathie-wood">Cathie Wood</a> may both be stock-picking legends, but their portfolios might as well be from different galaxies. While Buffett cruises the investing seas with old-school juggernauts, Wood launches rockets hoping they'll land on the moon &#8211; or at least avoid burning up on re-entry.
<h2 class="wp-block-heading">Tech Vs. Tact: A Tale Of Two Strategies</h2>
Data from HedgeFollow <a href="https://hedgefollow.com/funds/Berkshire+Hathaway" target="_blank" rel="noopener">suggests that</a> in the fourth quarter of 2024, Buffett's Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) clocked in a respectable 2.74% gain, quietly pushing his war chest to a towering $267 billion.
Meanwhile, Cathie Wood's ARK Innovation Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) lit up with a scorching 23.82% quarterly return &#8211; but before ARK fans pop champagne, the long-term picture tells a more sobering story.
Over the past three years, Buffett's top 50 holdings (weighted) returned +20.29%, while Wood's delivered a bruising -33.63%. That's not just a bad quarter &#8211; it's a full-blown crash landing.
<h2 class="wp-block-heading">Buffett's Billion-Dollar Boring Works Brilliantly</h2>
The difference? 
Buffett's portfolio is a fortress of slow-burning compounders. His crown jewel, Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), takes up 28% of his portfolio and has returned a jaw-dropping +438.8% from its average buy price.
Throw in American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) (+277.6%), Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) (+55.8%) and Coca-Cola Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) (+77%), and it's clear the Oracle of Omaha is still the king of buying great companies at great prices… and holding them forever.
Read Also: <a href="https://www.benzinga.com/25/04/44969765/cathie-wood-buys-more-nvidia-and-amd-stock-as-chinese-tech-giants-stockpile-chips-amid-looming-us-export-curbs">Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs</a>
<h2 class="wp-block-heading">Cathie's High-Flyers Keep Crashing Back To Earth</h2>
Cathie Wood, on the other hand, is all about "disruption" — and sometimes, the disruption is in her portfolio&#8217;s value. Take Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), down 46.6% from her average buy-in, and Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), down -50.1%. Her top bets, like Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), have had moments of glory, but the overall portfolio has been whipsawed by volatility and drawn-out tech drawdowns.
To her credit, Wood&#8217;s fourth-quarter comeback shows that high-beta bets can pay off—just not consistently. While her fund has a whopping 181 holdings, many are moonshots still waiting for liftoff.
Overall, Buffett's performance shows the power of patience and pricing. Wood? She's still betting on the future &#8211; but it seems Buffett is quietly owning it.
Which camp would you rather retire in &#8211; the steady compounder or the volatile visionary?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45029505/warren-buffett-reveals-the-one-easy-way-to-become-worth-50-more-than-you-are-now">Warren Buffett Reveals &#8216;The One Easy Way To Become Worth 50% More Than You Are Now&#8217;</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Hedge Funds

ETFs

AAPL

ARKK

COIN

ROKU

TSLA

Warren Buffett's Compounders Crush Cathie Wood's Disruptors Over The Long Haul

HC Wainwright &amp; Co. analyst Yi Chen maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Buy and lowers the price target from $20 to $15.

BLCO

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $15

Stifel analyst Stephen Gengaro maintains Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) with a Buy and lowers the price target from $28 to $27.

CVEO

Stifel Maintains Buy on Civeo, Lowers Price Target to $27

Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#CSE">DPRO</a>) (FSE: 3U8A) ("Draganfly" or the "Company"), a drone solutions, and systems developer, today announced the pricing of its previously announced underwritten public offering (the "Offering") of 1,715,000 units, with each unit consisting of one common share and one warrant to purchase one common share. Each unit is to be sold at a public offering price of US$2.10, for gross proceeds of approximately US$3.6 million, before deducting underwriting discounts and offering expenses. The warrants will have an exercise price of CA$3.9779 (or US$2.875) per share, are exercisable immediately and will expire five years following the date of issuance. In addition, the Company granted the underwriter a 45-day over-allotment option to purchase up to an additional 15 percent of the number of common shares and/or warrants offered in the Offering.

Offerings

CSE:DPRO

Draganfly Announces Pricing Of US$3.6M Underwritten Public Offering Of 1.71M Units At $2.10 Per Unit

PLPC

Preformed Line Products Acquires JAP Telecom; Terms Not Disclosed

Needham analyst Laura Martin maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and raises the price target from $135 to $145.

RDDT

Needham Maintains Buy on Reddit, Raises Price Target to $145

Stifel analyst Stephen Gengaro maintains Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) with a Buy and lowers the price target from $61 to $57.

Stifel Maintains Buy on Cactus, Lowers Price Target to $57

Stifel analyst David Grossman maintains American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) with a Hold and lowers the price target from $10 to $8.

AMWL

Stifel Maintains Hold on American Well, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) with a Buy and raises the price target from $1.5 to $7.

XFOR

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia
Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques
IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences&#xAE; (NASDAQ:<a href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the premier physician-led weight loss and metabolic health solutions company, today announced it will present pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium, being held in Minneapolis.

RSLS

ReShape Lifesciences To Present Pre-Clinical Data On Proprietary Diabetes Neuromodulation Device At 12Th Annual Minnesota Neuromodulation Symposium

Stifel analyst Mark Kelley maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and lowers the price target from $248 to $245.

AMZN

Stifel Maintains Buy on Amazon.com, Lowers Price Target to $245

<ul>
<li>Company Aims to Exceed 1,000 Advertisers by Mid-Q2 and 5,000 Advertisers by the End of 2025</li>
<li>Thumzup's Plans Further Accelerate Growth and Market Penetration of its Innovative AdTech Platform</li>
</ul>
LOS ANGELES, May 2, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418767-1&amp;h=2562076278&amp;u=https%3A%2F%2Fwww.thumzupmedia.com%2F&amp;a=Thumzup+Media+Corporation">Thumzup Media Corporation</a> ("Thumzup" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>), an emerging leader in social media branding and programmatic marketing solutions, is excited to announce it has surpassed 900 advertisers, a CAGR (Compound Annual Growth Rate) of 220%, marking a significant milestone in the Company's rapid expansion within the digital advertising space. Thumzup's growth trajectory remains strong, and the Company expects to reach 1,000 advertisers by mid-Q2 and 5,000 advertisers by the end of 2025.

TZUP

Thumzup Media Surpasses 900 Advertisers, CAGR Of 220%; Expects To Reach 1,000 Advertisers By Mid-Q2 And 5,000 Advertisers By 2025 End

Press Releases

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Akanda

Artelo Biosciences

CNS Pharma

Enveric Biosciences

Eyenovia

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

cbdMD

HC Wainwright & Co.

Benchmark

Oppenheimer

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 컨스텔레이션 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.
2. 리바이 스트라우스 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>)는 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B0%94%EC%9D%B4-%EC%8A%A4%ED%8A%B8%EB%9D%BC%EC%9A%B0%EC%8A%A4%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%80-%EC%97%87%EA%B0%88%EB%A6%B0-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%B0%9C%ED%91%9C/" target="_blank" rel="noopener">3분기 이익이 예상보다 좋았지만</a> 매출은 예상에 미달했다고 발표했다. 이 회사는 2024 회계연도 조정된 주당 이익을 1.17달러에서 1.27달러 사이로 예상하고 있으며, 이는 1.25달러의 예상치와 비교된다. 리바이 스트라우스의 주식은 애프터 마켓에서 10.9% 하락하여 18.76달러에 거래되고 있다.
3. 분석가들은 앤지오다이내믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>)가 최근 분기에 주당 15센트의 손실을 기록하고 매출이 6,793만 달러일 것으로 예상하고 있다. 이 회사는 개장 전에 실적을 발표할 예정이다. 앤지오다이내믹스의 주식은 애프터 마켓에서 2.1% 상승하여 7.81달러에 거래되었다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>
4. 빅커머스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>)는 트래비스 헤스(Travis Hess)를 CEO로 임명했다. 브렌트 벨름(Brent Bellm)은 더 이상 회사의 CEO 또는 이사회 의장을 맡지 않는다. 빅커머스의 주식은 애프터 마켓에서 1.4% 상승하여 5.75달러에 거래되고 있다.
5. 프로세사 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>)의 주식은 회사가 NGC-Cap의 2상 시험을 위한 첫 번째 환자를 투여했다고 발표한 후에 수요일 애프터 마켓에서 급등했다. 프로세사 파마슈티컬스의 주식은 애프터 마켓에서 3% 상승하여 1.37달러에 거래되었다.
이것도 확인해보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41156151/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">월스트리트의 가장 정확한 애널리스트들이 고배당 소비재 주식 3종목에 대한 의견을 제시</a></li>
</ul>
사진 제공: Constellation Brands
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Processa Pharmaceuticals

뉴스

에 대한 최신 뉴스 Processa Pharmaceuticals (NASDAQ:PCSA) 주식

목요일, 10월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌